N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.
We spoke with Nigel today and asked about the progress the company is making and shareholders question.
N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre-clinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market.
https://www.share-talk.com/nigel-theobald-ceo-of-n4-pharma-plc-n4p-l-interview/
https://www.share-talk.com/nigel-theobald-ceo-of-n4-pharma-plc-n4p-l-interview/
Listen On
Also Listen
-
Interview: Capital Metals – Advancing the Taprobane Minerals Project in Sri Lanka
Zak Mir talks to Greg Martyr, Executive Chairman, Capital Metals, in the wake of -
Interview with Jim Mellon: Insights on the 2025 Market Landscape and Investment Strategies
In a recent conversation with renowned investor Jim Mellon, Zak Mir delved deep -
Sam Garrett Chief Executive Officer of Great Southern Copper talking with Andrew Scott
Great Southern Copper plc (LSE: GSCU) continues to make exciting strides at its -
Zak Mir Talks to Howard White, Non-Executive Chairman of Hydrogen Utopia Intl
Zak Mir talks to Howard White, Chairman of Hydrogen Utopia, a company specialisi